PE20211446A1 - Formas de co-cristales de un analogo de novobiocina y prolina - Google Patents

Formas de co-cristales de un analogo de novobiocina y prolina

Info

Publication number
PE20211446A1
PE20211446A1 PE2020001199A PE2020001199A PE20211446A1 PE 20211446 A1 PE20211446 A1 PE 20211446A1 PE 2020001199 A PE2020001199 A PE 2020001199A PE 2020001199 A PE2020001199 A PE 2020001199A PE 20211446 A1 PE20211446 A1 PE 20211446A1
Authority
PE
Peru
Prior art keywords
novobiocin
analog
prolin
crystals
forms
Prior art date
Application number
PE2020001199A
Other languages
English (en)
Inventor
Xin Jiang
John Allen Walling
Melanie J Bevill
Christopher S Seadeek
Jared P Smit
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of PE20211446A1 publication Critical patent/PE20211446A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Referido a un co-cristal de N-(2-(5-(((2R,3R,4S,5R)-3,4-dihidroxi-5-metoxi-6,6-dimetiltetra-hidro-2H-piran-2-il)oxi)-3'-fluoro-[1,1'-bifenil]-2-il)etil)-acetamida (analogo de novobiocina) y L-prolina (1:2), caracterizado por un difractograma de polvo de rayos X que comprende los siguientes picos: 14,76, 16,86, 19,00 y 21,05 °2tetha ± 0,20 °2tetha determinado sobre un difractometro usando una radiacion de Cu-K_alfa a una longitud de onda de 1,54178 Å. Tambien se refiere a procesos de fabricacion, composiciones farmaceuticas y su uso para tratar trastornos neurodegenerativos tales como la neuropatia periferica diabetica.
PE2020001199A 2018-02-07 2019-02-01 Formas de co-cristales de un analogo de novobiocina y prolina PE20211446A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
PE20211446A1 true PE20211446A1 (es) 2021-08-05

Family

ID=65444361

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001199A PE20211446A1 (es) 2018-02-07 2019-02-01 Formas de co-cristales de un analogo de novobiocina y prolina

Country Status (17)

Country Link
US (3) US10717755B2 (es)
EP (1) EP3749675A1 (es)
JP (2) JP2021512910A (es)
CN (1) CN112020506B (es)
AR (1) AR114245A1 (es)
AU (2) AU2019217821B2 (es)
BR (1) BR112020016205A2 (es)
CA (2) CA3226385A1 (es)
CL (2) CL2020002051A1 (es)
CO (1) CO2020009761A2 (es)
EA (1) EA202091885A1 (es)
IL (1) IL276583A (es)
MX (2) MX2020008326A (es)
PE (1) PE20211446A1 (es)
SG (1) SG11202007530XA (es)
TW (2) TWI797249B (es)
WO (1) WO2019156907A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211446A1 (es) 2018-02-07 2021-08-05 Reata Pharmaceuticals Inc Formas de co-cristales de un analogo de novobiocina y prolina
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221049B (zh) * 2010-09-23 2015-11-25 诺弗米克斯有限公司 阿瑞匹坦l-脯氨酸组合物和共晶
US9035044B2 (en) * 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2013076659A1 (en) * 2011-11-25 2013-05-30 Nuformix Limited Aprepitant l-proline solvates - compositions and cocrystals
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
HRP20240514T1 (hr) * 2012-02-09 2024-07-05 The University Of Kansas Međuproizvodi za pripremu c-terminalnih inhibitora hsp90
ES2671478T3 (es) * 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CA2952029A1 (en) * 2014-06-24 2015-12-30 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
BR112017005454A2 (pt) * 2014-09-30 2017-12-12 Jiangsu Hengrui Medicine Co composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
PE20211446A1 (es) 2018-02-07 2021-08-05 Reata Pharmaceuticals Inc Formas de co-cristales de un analogo de novobiocina y prolina

Also Published As

Publication number Publication date
JP2021512910A (ja) 2021-05-20
CA3090646C (en) 2024-02-27
AU2022283638A1 (en) 2023-02-02
CL2022003784A1 (es) 2023-06-09
SG11202007530XA (en) 2020-09-29
TW201945381A (zh) 2019-12-01
TWI797249B (zh) 2023-04-01
US20190241599A1 (en) 2019-08-08
AU2019217821A1 (en) 2020-09-24
US10717755B2 (en) 2020-07-21
JP2024001167A (ja) 2024-01-09
MX2022012856A (es) 2022-11-30
US20240043465A1 (en) 2024-02-08
CN112020506A (zh) 2020-12-01
EP3749675A1 (en) 2020-12-16
CN112020506B (zh) 2024-10-11
EA202091885A1 (ru) 2021-01-15
US11401294B2 (en) 2022-08-02
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
WO2019156907A1 (en) 2019-08-15
US20200347088A1 (en) 2020-11-05
AU2022283638B2 (en) 2024-07-25
IL276583A (en) 2020-09-30
CL2020002051A1 (es) 2021-02-19
CA3090646A1 (en) 2019-08-15
AR114245A1 (es) 2020-08-12
BR112020016205A2 (pt) 2020-12-15
AU2019217821B2 (en) 2022-09-08
MX2020008326A (es) 2020-09-28
CO2020009761A2 (es) 2020-10-30

Similar Documents

Publication Publication Date Title
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
PE20211446A1 (es) Formas de co-cristales de un analogo de novobiocina y prolina
DOP2021000148A (es) Compuestos moduladores de fxr (nr1h4)
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
CL2021002959A1 (es) Nuevas formas sólidas de ácido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7- hidroxi-1-propil-1,2,3,4,4a,5,10,10a- octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro2h-piran-2-carboxílico.
CL2012001461A1 (es) Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras.
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
BRPI0817096A8 (pt) Análogo de tiazolidinodiona e composição farmacêutica que o compreende
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
BR112013019955A2 (pt) n-[3-(5-amino-3,3a,7,7a-tetra-hidro-1h-2,4-dioxa-6-aza-inden-7-il)-fenil]-amidas como inibidores de bace1 e/ou de bace2
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
AR096582A1 (es) Procesos de fabricación y formas cristalinas de un inhibidor de mdm2
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
CL2021002961A1 (es) Un procedimiento para la fabricación de ácido(2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7-hidroxi-1-propil-1,2,3,4,4a, 5,10,10a-octahidrobenzo[g]quinolin-6-il)oxi) tetrahidro-2h-piran-2-carboxílico.
CL2009000381A1 (es) Compuestos derivados de tiazol o tiazol-5-carboxamida, inhibidores de la actividad estearoil-coa-desaturasa humana (scd); composicion farmaceutica; y uso para el tratamiento de un trastorno o enfermedad mediada por las enzimas de scd, tal como diabetes, obesidad, enfermedad cardiovascular, lipidos elevados, entre otras.
FI3653625T3 (fi) Mgat-2-estävää aktiivisuutta omaava fuusioituneen renkaan johdannainen
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CO2019002673A2 (es) Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CR20170209A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
NZ629778A (en) C-terminal hsp90 inhibitors
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso